The New Jersey Supreme Court is chewing over a case that will decide whether Merck & Co. must pay a projected $35 million tab for medical monitoring of people who may have suffered “silent heart attacks” from use of its drug Vioxx.
The putative class action suit, Sinclair v. Merck & Co. Inc., A-117-06, was filed on behalf of about 233,000 people who took the painkiller before its recall from the market in 2004 amid revelations of adverse cardiovascular effects. Thousands of individual and class action suits have since been lodged against the Whitehouse Station, N.J., manufacturer.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
